{"database": "lobbying", "table": "lobbying_activities", "rows": [[2152031, "92683c5b-e7cb-4e3a-9bf0-56bca99ce957", "Q2", "HOOPER, LUNDY & BOOKMAN, P.C.", 401020884, "BROWN RUDNICK, LLP, ON BEHALF OF PRIME THERAPEUTICS", 2018, "second_quarter", "MMM", "H.R. 1316-The Prescription Drug Price Transparency Act (MAC); H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); H.R. 1939 & S. 1044 - Ensuring Seniors Access to Local Pharmacies Act of 2017; S. 2553-Know the Lowest Price Act. CY2019 Medicare Part D Final Rule relating to direct and indirect renumeration fees; H.R.5958-The Phair Pricing Act of 2018.", "HOUSE OF REPRESENTATIVES,SENATE", 10000, null, 0, 0, "2018-07-18T18:09:20.823000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2152031"], "units": {}, "query_ms": 0.4399020690470934, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}